BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application. Res Rep Urol 2017;9:129-39. [PMID: 28791261 DOI: 10.2147/RRU.S141748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Babu A, Kayes O. Recent advances in managing Peyronie's disease. F1000Res 2020;9:F1000 Faculty Rev-381. [PMID: 32518629 DOI: 10.12688/f1000research.20557.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lourens W. Could coenzyme Q10 be the treatment for Dupuytren's disease? BMJ Case Rep 2019;12:e226419. [PMID: 30826776 DOI: 10.1136/bcr-2018-226419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Geng Q, Wang F, Han Q, Chen SF, Ouyang B, Li Z, Zhao Y, Gao QH, Yu GJ, Guo J. Antioxidant Mechanism of Xiaojin Pill () for Treatment of Peyronie's Disease in Rats Based on Matrix Metalloproteinases. Chin J Integr Med 2019;25:671-6. [PMID: 31650486 DOI: 10.1007/s11655-019-3203-7] [Reference Citation Analysis]
4 Moghalu OI, Das R, Horns J, Campbell A, Hotaling JM, Pastuszak AW. Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database. Int J Impot Res 2021. [PMID: 33828265 DOI: 10.1038/s41443-021-00430-x] [Reference Citation Analysis]